News Article

EssilorLuxottica has closed the purchase of Optegra, a 70-clinic ophthalmology network spanning the UK, Czech Republic, Poland, Slovakia and the Netherlands. The transaction vaults the group from a dominant eyewear manufacturer-retailer into a vertically integrated eye-health services platform capable of owning the entire patient journey—from screening and diagnosis to surgery, prescription, and connected eyewear. How will this reshape the global vision care landscape?

Optegra’s 70 eye hospitals and diagnostic centres deliver reimbursed cataract, glaucoma and AMD treatments alongside elective laser and refractive lens procedures. Integrating these assets expands EssilorLuxottica’s historic revenue mix of frames, lenses and retail into surgical services—an adjacent field growing at a mid-single-digit pace and offering structurally higher lifetime-value per patient.

Strategically, the deal plugs a gap in the group’s “full-circle” model. Its 18,000 optical stores already capture prescription, dispensing and after-sales follow-up; smart eyewear (Ray-Ban Meta, Oakley Meta) adds real-time health monitoring; now, Optegra brings in-house diagnostics and treatment.

The end-to-end platform unlocks cross-selling: Optegra patients can funnel into LensCrafters for post-op eyewear; retail customers diagnosed with cataracts during store screenings can be referred to Optegra surgeons, tightening retention while boosting medical case volume.

From an operator perspective, partnership opportunities include co-developing AI diagnostics and leveraging EssilorLuxottica’s retail footfall to boost clinic utilisation. From an investor point of view, the deal reinforces the thesis that the company is morphing from a consumer-luxury conglomerate into a diversified healthcare technology leader, deserving of a rerated valuation closer to MedTech peers.